A Phase II Study of S-1 and Paclitaxel Combination Therapy as a First-Line Treatment in Elderly Patients with Advanced Non-Small Cell Lung Cancer.
Adenocarcinoma of Lung
/ drug therapy
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
/ therapeutic use
Carcinoma, Non-Small-Cell Lung
/ drug therapy
Carcinoma, Squamous Cell
/ drug therapy
Drug Combinations
Female
Follow-Up Studies
Humans
Lung Neoplasms
/ drug therapy
Male
Oxonic Acid
/ administration & dosage
Paclitaxel
/ administration & dosage
Prognosis
Survival Rate
Tegafur
/ administration & dosage
Journal
The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837
Informations de publication
Date de publication:
04 2019
04 2019
Historique:
received:
02
10
2018
accepted:
23
11
2018
pubmed:
24
12
2018
medline:
21
5
2020
entrez:
23
12
2018
Statut:
ppublish
Résumé
Coadministration of S-1 and paclitaxel in elderly patients with advanced non-small cell lung cancer showed favorable efficacy.Coadministration of S-1 and paclitaxel in elderly patients with advanced non-small lung cancer showed tolerable toxicity. Although monotherapy with cytotoxic agents including docetaxel or vinorelbine are recommended for elderly patients with advanced non-small cell lung cancer (NSCLC), the outcome is not satisfactory. We evaluated the efficacy and safety of S-1 and paclitaxel (PTX) as a first-line cotreatment in elderly patients with advanced NSCLC. Oral S-1 was administered on days 1-14 every 3 weeks at 80, 100, and 120 mg per day for patients with body surface area < 1.25 m Seventeen patients were enrolled with response and disease control rates of 47.1% and 88.2%, respectively. Median PFS and OS were 5.6 and 35.0 months, respectively. Hematological grade 3 or 4 toxicities included leukopenia (55.8%), neutropenia (52.9%), febrile neutropenia (11.8%), and anemia (11.8%). Nonhematological grade 3 toxicities included stomatitis (23.5%), diarrhea (5.9%), and interstitial lung disease (5.9%), and grade 5 toxicities included interstitial lung disease (5.9%). This S-1 and PTX cotherapy dose and schedule showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC.
Sections du résumé
LESSONS LEARNED
Coadministration of S-1 and paclitaxel in elderly patients with advanced non-small cell lung cancer showed favorable efficacy.Coadministration of S-1 and paclitaxel in elderly patients with advanced non-small lung cancer showed tolerable toxicity.
BACKGROUND
Although monotherapy with cytotoxic agents including docetaxel or vinorelbine are recommended for elderly patients with advanced non-small cell lung cancer (NSCLC), the outcome is not satisfactory. We evaluated the efficacy and safety of S-1 and paclitaxel (PTX) as a first-line cotreatment in elderly patients with advanced NSCLC.
METHODS
Oral S-1 was administered on days 1-14 every 3 weeks at 80, 100, and 120 mg per day for patients with body surface area < 1.25 m
RESULTS
Seventeen patients were enrolled with response and disease control rates of 47.1% and 88.2%, respectively. Median PFS and OS were 5.6 and 35.0 months, respectively. Hematological grade 3 or 4 toxicities included leukopenia (55.8%), neutropenia (52.9%), febrile neutropenia (11.8%), and anemia (11.8%). Nonhematological grade 3 toxicities included stomatitis (23.5%), diarrhea (5.9%), and interstitial lung disease (5.9%), and grade 5 toxicities included interstitial lung disease (5.9%).
CONCLUSION
This S-1 and PTX cotherapy dose and schedule showed satisfactory efficacy with mild toxicities in elderly patients with advanced NSCLC.
Identifiants
pubmed: 30578309
pii: theoncologist.2018-0858
doi: 10.1634/theoncologist.2018-0858
pmc: PMC6459255
doi:
Substances chimiques
Drug Combinations
0
S 1 (combination)
150863-82-4
Tegafur
1548R74NSZ
Oxonic Acid
5VT6420TIG
Paclitaxel
P88XT4IS4D
Banques de données
UMIN-CTR
['UMIN000003782']
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
459-e131Informations de copyright
© AlphaMed Press; the data published online to support this summary are the property of the authors.
Références
Br J Cancer. 2003 Mar 24;88(6):957-64
pubmed: 12644837
Invest New Drugs. 2019 Apr;37(2):291-296
pubmed: 30121935
Lung Cancer. 2009 Oct;66(1):103-6
pubmed: 19193470
J Natl Cancer Inst. 1999 Jan 6;91(1):66-72
pubmed: 9890172
J Natl Cancer Inst. 2003 Mar 5;95(5):362-72
pubmed: 12618501
Int J Oncol. 2004 Dec;25(6):1531-6
pubmed: 15547687
Clin Cancer Res. 2000 Apr;6(4):1322-7
pubmed: 10778957
Chemotherapy. 2012;58(6):454-60
pubmed: 23392470
Br J Cancer. 2006 Dec 18;95(12):1642-7
pubmed: 17133268
Cancer. 2012 Nov 15;118(22):5588-94
pubmed: 22569898
Expert Opin Pharmacother. 2015 Mar;16(4):465-72
pubmed: 25597331
Anticancer Drugs. 2011 Sep;22(8):811-6
pubmed: 21317767
Clin Cancer Res. 2001 Dec;7(12):3942-9
pubmed: 11751486
Lung Cancer. 2010 Aug;69(2):213-7
pubmed: 20153912
Cancer Chemother Pharmacol. 2008 Nov;62(6):1103-9
pubmed: 18317763
Gan To Kagaku Ryoho. 2009 Mar;36(3):417-24
pubmed: 19295265
CA Cancer J Clin. 2015 Jan-Feb;65(1):5-29
pubmed: 25559415
Oncol Lett. 2017 Jul;14(1):1123-1128
pubmed: 28693283
J Clin Oncol. 2015 Feb 20;33(6):575-81
pubmed: 25584004
Lung Cancer. 2015 Feb;87(2):193-200
pubmed: 25564398
Anticancer Res. 2008 May-Jun;28(3A):1593-602
pubmed: 18630517
Lancet. 2011 Sep 17;378(9796):1079-88
pubmed: 21831418
J Clin Oncol. 2000 Jul;18(13):2529-36
pubmed: 10893283
Cancer Chemother Pharmacol. 2000;46(2):114-8
pubmed: 10972480
J Clin Oncol. 2006 Aug 1;24(22):3657-63
pubmed: 16877734
Cochrane Database Syst Rev. 2015 Oct 20;(10):CD010463
pubmed: 26482542